1. MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy
   Mette S. van Ramshorst et al, 2017, Breast Cancer Res Treat CrossRef
2. Use Case III: Imaging Biomarkers in Breast Tumours. Development and Clinical Integration
   M. A. Marino et al, 2017 CrossRef
3. Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging
   Hiroshi Kaise et al, 2018, Journal of Surgical Research CrossRef
4. How Does MR Imaging Help Care for the Breast Cancer Patient? Perspective of a Medical Oncologist
   Akshara S. Raghavendra et al, 2018, Magnetic Resonance Imaging Clinics of North America CrossRef
5. Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy
   Eunhae Um et al, 2018, Clinical Breast Cancer CrossRef
6. Pretreatment MRI features associated with diagnostic accuracy of post-treatment MRI after neoadjuvant chemotherapy
   N.L. Eun et al, 2018, Clinical Radiology CrossRef
7. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype
   Maki Namura et al, 2018, Clinical Breast Cancer CrossRef
8. Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial
   Caitlin Murphy et al, 2018, Intern Med J CrossRef
9. A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features
   Ashirbani Saha et al, 2018, Br J Cancer CrossRef
10. Breast Cancer
    Elizabeth A. M. O’Flynn, 2014 CrossRef
11. Multimodality Imaging for Evaluating Response to Neoadjuvant Chemotherapy in Breast Cancer
    Gaiane M. Rauch et al, 2017, American Journal of Roentgenology CrossRef
12. Breast Magnetic Resonance Imaging for Monitoring Response to Therapy
    Haydee Ojeda-Fournier et al, 2013, Magnetic Resonance Imaging Clinics of North America CrossRef
13. Complete Breast MRI Response to Neoadjuvant Chemotherapy and Prediction of Pathologic Complete Response
    Christina A Chen et al, 2019 CrossRef
14. Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology
    Jeon-Hor Chen et al, 2014, J. Surg. Oncol. CrossRef
15. Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated With Neoadjuvant Systemic Treatment for Operable Breast Cancer: Translational Breast Cancer Research Consortium Trial 017
    M.-Y.L. Su, 2013, Breast Diseases: A Year Book Quarterly CrossRef
16. Analysis of Factors that Influence the Accuracy of Magnetic Resonance Imaging for Predicting Response after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
    M.-Y.L. Su, 2014, Breast Diseases: A Year Book Quarterly CrossRef
17. Effect of breast cancer phenotype on diagnostic performance of MRI in the prediction to response to neoadjuvant treatment
    Enida Bufi et al, 2014, European Journal of Radiology CrossRef
18. Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
    M.-Y.L. Su, 2014, Breast Diseases: A Year Book Quarterly CrossRef
19. Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population
    Nataliya Babyshkina et al, 2014, Med Oncol CrossRef
20. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer
    A. Charehbili et al, 2014, European Journal of Surgical Oncology (EJSO) CrossRef
21. Molecular Classification of Infiltrating Breast Cancer: Toward Personalized Therapy
    Isabelle Trop et al, 2014, RadioGraphics CrossRef
22. Can Breast Cancer Molecular Subtype Help to Select Patients for Preoperative MR Imaging?
    Lars J. Grimm et al, 2015, Radiology CrossRef
23. Accuracy of breast magnetic resonance imaging in evaluating the response to neoadjuvant chemotherapy: a study of 310 cases at a cancer center
    Erika Marina Solla Negrão et al, 2019, Radiol Bras CrossRef
24. Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim 18F-FDG PET/CT and MRI.
    Kisoo Pahk et al, 2015, Nucl Med Commun CrossRef
25. Breast Cancer: Influence of Taxanes on Response Assessment with Dynamic Contrast-enhanced MR Imaging
    Simone Schrading et al, 2015, Radiology CrossRef
26. Breast MRI radiogenomics: Current status and research implications
    Lars J. Grimm, 2016, J. Magn. Reson. Imaging CrossRef
27. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
    Claudette E. Loo et al, 2016, Breast Cancer Res CrossRef
28. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response
    Gorane Santamaría et al, 2017, Radiology CrossRef
29. MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer
    Cynthia Brito Lins Pereira et al, 2017, Clinical Breast Cancer CrossRef
30. Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysis.
    Yan-Lin Gu et al, 2017, Clin Breast Cancer CrossRef
31. Multiparametric Evaluation of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer Using Integrated PET/MR
    Jane Wang et al, 2017, Clinical Nuclear Medicine CrossRef
32. Breast Cancer Phenotype Influences MRI Response Evaluation after Neoadjuvant Chemotherapy
    Erika M.S. Negrão et al, 2019, European Journal of Radiology CrossRef
33. Attributes, Performance, and Gaps in Current & Emerging Breast Cancer Screening Technologies
    Hina M. Ismail et al, 2019, CMIR CrossRef
34. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple‐Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival
    Ruo‐Xi Wang et al, 2019, The Oncol CrossRef
35. Imaging for Response Assessment in Cancer Clinical Trials
    Anna G. Sorace et al, 2020, Seminars in Nuclear Medicine CrossRef
36. The diagnostic performance of CESM and CE-MRI in evaluating the pathological response to neoadjuvant therapy in breast cancer: a systematic review and meta-analysis
    Sudan Tang et al, 2020, BJR CrossRef
37. Nomogram for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using Dynamic Contrast-enhanced and Diffusion-weighted MRI
    Rui Zhao et al, 2021, Academic Radiology CrossRef
38. Evaluation of Post-Neoadjuvant Chemotherapy Pathologic Complete Response and Residual Tumor Size of Breast Cancer: Analysis on Accuracy of MRI and Affecting Factors
    Hyun Soo Ahn et al, 2021, J Korean Soc Radiol CrossRef
39. Can breast MRI and adjunctive Doppler ultrasound improve the accuracy of predicting pathological complete response after neoadjuvant chemotherapy?
    Kazuaki Nakashima et al, 2021, Breast Cancer CrossRef
40. Kinetic information from dynamic contrast-enhanced MRI enables prediction of residual cancer burden and prognosis in triple-negative breast cancer: a retrospective study
    Ayane Yamaguchi et al, 2021, Sci Rep CrossRef
41. Multi‐parametric MRI (mpMRI) for treatment response assessment of radiation therapy
    Chunhao Wang et al, 2021, Med. Phys. CrossRef
42. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes
    Jieun Kim et al, 2022, Eur Radiol CrossRef
43. Role of MRI in predicting response to neo-adjuvant systemic therapy (NAST) in breast cancer
    Sadaf Jafferbhoy et al, 2022, BD CrossRef
44. Factors associated with radiologic-pathologic discordance in magnetic resonance imaging after neoadjuvant chemotherapy for breast cancer
    Mi-ri Kwon et al, 2022, Clinical Imaging CrossRef
45. Identification of tumor biomarkers for pathological complete response to neoadjuvant treatment in locally advanced breast cancer
    Prarthana Gopinath et al, 2022, Breast Cancer Res Treat CrossRef
46. SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival
    Ruo-Xi Wang et al, 2022, Front. Immunol. CrossRef
47. Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis
    Roxanne A. W. Ploumen et al, 2023, Eur Radiol CrossRef
48. Can breast MRI predict pathologic response following neoadjuvant chemotherapy for breast cancer? A retrospective cohort study
    Lily Kwak et al, 2023, Clinical Imaging CrossRef
49. MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
    Anna van der Voort et al, 2024, The Lancet Oncology CrossRef
50. Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer
    Anna van der Voort et al, 2024, Eur Radiol CrossRef
51. Performance of Contrast-Enhanced Mammography (CEM) for Monitoring Neoadjuvant Chemotherapy Response among Different Breast Cancer Subtypes
    Sofia Vidali et al, 2024, Cancers CrossRef